ST
UTHR icon

Spot Trading’s United Therapeutics UTHR Stock Holding History

Spot Trading’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,489
Closed -$446K – 3397
2017
Q2 		$453K Buy
3,489
+2,887
+480% +$360K 0.01% 1668
2017
Q1 		$81K Buy
602
+336
+126% +$50.9K ﹤0.01% 2344
2016
Q4 		$38K Buy
266
+229
+619% +$29.2K ﹤0.01% 2452
2016
Q3 		$4K Sell
37
-939
-96% -$113K ﹤0.01% 2961
2016
Q2 		$103K Buy
+976
New +$109K ﹤0.01% 2523
2015
Q2 		– Sell
-1,362
Closed -$235K – 4285
2015
Q1 		$235K Buy
+1,362
New +$208K ﹤0.01% 2637
2014
Q4 		– Sell
-1,472
Closed -$189K – 4428
2014
Q3 		$189K Buy
+1,472
New +$152K ﹤0.01% 3223
2014
Q2 		– Sell
-4,280
Closed -$402K – 4842
2014
Q1 		$402K Buy
4,280
+4,087
+2,118% +$418K ﹤0.01% 2706
2013
Q4 		$22K Buy
+193
New +$17.4K ﹤0.01% 3664
2013
Q3 		– Sell
-1,417
Closed -$104K – 4458
2013
Q2 		$93K Buy
+1,417
New +$91.3K ﹤0.01% 3466

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Spot Trading's UTHR Position: Q3 2017 in Review

Spot Trading sold out of United Therapeutics (UTHR) in Q3 2017, closing a stake of 3,489 shares — an estimated $446K sold.

Spot Trading first reported a position in UTHR in Q2 2013 and held it in 10 quarters. The position peaked at $453K in Q2 2017. 373 funds tracked by Wall St. Rank hold UTHR as of Q3 2017.

  • Spot Trading reported no remaining United Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Spot Trading sold 3,489 United Therapeutics shares in Q3 2017, an estimated $446K.
  • Spot Trading first reported a position in United Therapeutics in Q2 2013 and held it in 10 quarters.
  • Spot Trading's United Therapeutics position peaked at $453K in Q2 2017.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2017.

Based on Spot Trading's 13F filing for Q3 2017, filed 6 Nov 2017.